Novartis calls Dendreon 'an enabler, not a failure'

If Novartis is to be believed, Dendreon – which earlier this week put in motion Chapter 11 bankruptcy proceedings (scripintelligence.com, 10 November 2014) – is not a failure, but an enabler for the next generation of cell immunotherapies. This came from Dr Usman Azam, global head of Novartis's recently established Cell and Gene Therapies Unit, speaking at the Advanced Therapies Investor Day held in London on 13 November.

If Novartis is to be believed, Dendreon – which earlier this week put in motion Chapter 11 bankruptcy proceedings (scripintelligence.com, 10 November 2014) – is not a failure, but an enabler for the next generation of cell immunotherapies. This came from Dr Usman Azam, global head of Novartis's recently established Cell and Gene Therapies Unit, speaking at the Advanced Therapies Investor Day held in London on 13 November.

Dendreon is a regarded as a victim of first-mover disadvantage, and its trials and tribulations are being lauded as a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anticancer

GSK’s Blenrep US Setback Could Go From Bad To Worse

 

With a US approval any time soon now looking unlikely, analysts are revising Blenrep’s peak sales guidance downwards.

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.

Dispatch Uses ‘Flare’ To Send CAR-Ts To Solid Tumors

 

With $216m in initial funding, the newly launched company is aiming to develop a cell therapy-based universal immuno-oncology option for solid tumor indications.

After Gilead Deal, Hookipa Hangs Up Its Hat

 
• By 

The Austrian firm is delisting from the NASDAQ and closing down.

More from Therapy Areas

Memo Therapeutics Plans BK Virus Therapy Phase III Despite Trial Miss

 
• By 

Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By 

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By 

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.